1. Introduction
2. The PD-1/PD-L1 Immune Checkpoint Pathway: Molecular Biology and Regulation
2.1. Structure and Physiological Function of PD-1/PD-L1 Signaling
2.2. PD-1/PD-L1-Mediated Immune Escape in Cancer
2.3. Relevance of PD-1/PD-L1 Biology to Thyroid Cancer
3. The Tumor Immune Microenvironment of Thyroid Cancer and Its Interaction With the PD-1/PD-L1 Axis
3.1. The Immune Landscape of Thyroid Cancer
3.2. Tumor-Infiltrating Lymphocytes and T-Cell Exhaustion
3.3. Tumor-Associated Macrophages and Immune Suppression
3.4. Regulatory T Cells and Myeloid-Derived Suppressor Cells
3.5. Cancer-Associated Fibroblasts and Stromal Regulation of Immune Escape
4. Molecular Regulation of PD-L1 Expression in Thyroid Cancer
4.1. Overview
| Molecular Pathway / Alteration | Mechanism of PD-L1 Regulation | Association with Thyroid Cancer | Potential Therapeutic Implication |
|---|---|---|---|
| BRAF V600E mutation | Activates RAF-MEK-ERK signaling, leading to transcriptional activation of immune checkpoint-related genes and increased PD-L1 expression; also linked to reduced MHC class I expression. | Common in papillary thyroid carcinoma and associated with aggressive features such as extrathyroidal extension and lymph node metastasis; the correlation with PD-L1 is not uniform across studies. | Combination of BRAF/MEK inhibitors with PD-1/PD-L1 blockade may enhance immune response. |
| MAPK pathway activation (BRAF, RAS, RET alterations) | Persistent MAPK signaling promotes inflammatory cytokine production, tumor cell survival and checkpoint upregulation. | Central driver pathway in differentiated thyroid carcinoma. | MAPK inhibition may modify the tumor immune microenvironment and improve immunotherapy efficacy. |
| PI3K/AKT/mTOR pathway activation | Enhances PD-L1 translation and protein stability through downstream signaling and promotes immunosuppressive tumor behavior. | Frequently involved in advanced and poorly differentiated thyroid cancers. | Targeting PI3K/AKT/mTOR signaling may overcome immune resistance mechanisms. |
| IFN-gamma/JAK/STAT pathway | IFN-gamma released by activated T cells induces STAT1 and IRF-1 activation and PD-L1 transcription (adaptive immune resistance). | A major mechanism of PD-L1 induction in immune-infiltrated thyroid tumors. | Indicates that PD-L1 expression may reflect both immune activation and immune suppression. |
| HIF-1alpha / hypoxia signaling | Hypoxic stress induces HIF-1alpha binding to the PD-L1 promoter, increasing PD-L1 expression. | Relevant in aggressive thyroid cancers with necrosis, rapid growth and poor vascular organization. | Targeting hypoxia-related pathways may improve response to checkpoint blockade. |
| TERT promoter mutations | May indirectly promote immune escape through genomic instability and tumor evolution. | Associated with poorly differentiated and anaplastic thyroid carcinoma, especially when co-occurring with BRAF V600E. | May identify high-risk patients requiring novel therapeutic strategies. |
| Epigenetic and post-transcriptional regulation | DNA methylation, histone modification and chromatin remodeling influence CD274 transcription; specific microRNAs regulate PD-L1 mRNA stability and translation. | Contributes to tumor heterogeneity and variable PD-L1 expression; an emerging mechanism in thyroid cancer immune regulation. | Epigenetic therapies may enhance tumor immunogenicity; microRNAs are potential biomarkers or therapeutic targets. |
| Tumor-associated inflammatory cytokines (IL-6, TNF-alpha, TGF-beta) | Promote immune suppression and may indirectly enhance PD-L1 expression through inflammatory signaling networks. | Contribute to the immunosuppressive tumor microenvironment, especially in advanced disease. | Cytokine modulation may represent an additional immunotherapeutic strategy. |
4.2. BRAF V600E Mutation and PD-L1 Expression
4.3. MAPK Pathway Activation and Immune Checkpoint Regulation
4.4. PI3K/AKT/mTOR Pathway
4.5. RET and RAS Alterations
4.6. TERT Promoter Mutations and Immune Escape
4.7. Cytokine Signaling, IFN-Gamma and Adaptive PD-L1 Expression
4.8. Hypoxia, Epigenetic and Post-Transcriptional Regulation
5. PD-1/PD-L1 Expression Across Thyroid Cancer Subtypes
5.1. Overview of Expression Patterns
| Thyroid Cancer Subtype | PD-1/PD-L1 Expression Pattern | Major Molecular Features | Clinical Implications |
|---|---|---|---|
| Papillary thyroid carcinoma (PTC) | Detected in tumor cells and tumor-infiltrating immune cells; reported positivity varies widely (approximately 6 - 53%) according to antibody and threshold, and may increase in aggressive tumors. | Frequent BRAF V600E mutation, MAPK pathway activation, RET rearrangements; inflammatory signaling may contribute to PD-L1 induction. | Associated in some studies and in meta-analysis with extrathyroidal extension, lymph node metastasis and shorter disease-free survival. Potential role for immunotherapy in selected advanced cases. |
| Follicular thyroid carcinoma | Reported in a subset of cases (tumoral positivity approximately 7.6% in a large screening series); less extensively studied than PTC. | Frequent RAS mutations, PI3K/AKT pathway alterations, changes affecting thyroid differentiation. | Clinical significance remains uncertain. Further studies are needed to determine whether PD-L1 can predict immunotherapy response. |
| Medullary thyroid carcinoma (MTC) | Highly variable between series, from very low expression to positivity in roughly one quarter of tumors, with weak to moderate intensity. | RET mutations/rearrangements; activation of MAPK and PI3K/AKT signaling. | Associations with distant metastasis and recurrence are inconsistent, and no objective responses were seen in the small prospective medullary thyroid carcinoma cohort treated with dual checkpoint blockade. Predictive biomarkers require validation. |
| Poorly differentiated thyroid carcinoma | Increased PD-1 and PD-L1 expression compared with differentiated thyroid cancers. | Accumulation of aggressive molecular alterations including TERT promoter mutations, TP53 abnormalities, MAPK and PI3K pathway activation. | Biologically aggressive group with potential sensitivity to checkpoint inhibition; included with anaplastic thyroid carcinoma (ATC) in combination trials. |
| ATC | Highest frequency of PD-L1 expression among thyroid cancers, although reported rates range from about 20% to over 80% depending on methodology. | High genomic instability, frequent TP53 alterations, TERT promoter mutations, BRAF alterations, inflammatory tumor microenvironment. | Strongest rationale for PD-1/PD-L1 blockade. Combination with mutation-matched targeted therapy, multikinase inhibitors and radiotherapy has produced the longest survival reported to date in ATC. |
5.2. PTC
5.3. FTC
5.4. MTC
5.5. PDTC
5.6. ATC
6. Clinical Significance of PD-1/PD-L1 in Thyroid Cancer: Prognostic Value, Diagnostic Utility, and Predictive Biomarker Potential
6.1. PD-L1 as a Prognostic Biomarker
6.2. Diagnostic Utility of PD-L1 in Thyroid Nodules
6.3. PD-L1 as a Predictive Biomarker for Immune Checkpoint Inhibition
6.4. Beyond PD-L1: Integrated Biomarker Strategies
6.5. Limitations of PD-L1 Assessment
6.5.1. Immunohistochemical Variability
6.5.2. Tumor Heterogeneity
6.5.3. Dynamic Regulation
7. Therapeutic Landscape of PD-1/PD-L1 Blockade in Thyroid Cancer
7.1. Rationale for Immune Checkpoint Blockade
7.2. PD-1 Blockade in Differentiated and Radioiodine-Refractory Thyroid Cancer
7.3. Immune Checkpoint Inhibition in Medullary Thyroid Carcinoma
7.4. Immune Checkpoint Inhibition in Anaplastic and Poorly Differentiated Thyroid Carcinoma
| Study / Drug | Design and phase | Patient Population | Treatment Strategy | Main Findings | Clinical Significance |
|---|---|---|---|---|---|
| Mehnert et al., KEYNOTE-028 (pembrolizumab) (62) | Phase 1b, nonrandomized | 22 patients with advanced PD-L1-positive papillary or follicular thyroid cancer | Pembrolizumab monotherapy | ORR 9.1% (2 partial responses); 6-month PFS 58.7%; manageable safety profile | First clinical evidence supporting PD-1 blockade in selected thyroid cancer patients |
| Oh et al., KEYNOTE-158 (pembrolizumab) (58) | Phase 2, single-arm, multicohort | 103 patients with previously treated advanced papillary or follicular thyroid carcinoma, regardless of PD-L1 status | Pembrolizumab monotherapy | ORR 6.8%; median duration of response 18.4 months; responses independent of PD-L1 status; ~50% alive at 3 years | Durable benefit in a small minority; PD-L1 alone does not predict response, highlighting the need for better biomarkers |
| Capdevila et al., spartalizumab (PDR001) (59) | Phase 2 cohort of a phase 1/2 study | 42 patients with locally advanced or metastatic anaplastic thyroid carcinoma | Anti-PD-1 monotherapy, 400 mg every 4 weeks | ORR 19% (3 complete, 5 partial responses); all responses in PD-L1-positive tumors, with response rate rising with PD-L1 level | First trial to show responsiveness of ATC to PD-1 blockade; supports PD-L1-guided selection in this subtype |
| Sehgal et al., nivolumab plus ipilimumab (33) | Phase 2, nonrandomized, single center | 32 RAI-refractory DTC (primary cohort), 7 MTC and 10 ATC (exploratory cohorts) | Dual checkpoint blockade (anti-PD-1 plus anti-CTLA-4) | ORR 9.4% in RAI-refractory DTC (primary endpoint not met); ORR 30% in ATC; no responses in MTC; NRAS alterations linked to worse outcome | Does not support dual blockade in unselected DTC or MTC; the ATC signal merits further evaluation |
| Dierks et al., lenvatinib plus pembrolizumab (67) | Retrospective series | Patients with ATC and PDTC | Anti-PD-1 therapy combined with a VEGFR-targeting multikinase inhibitor | Complete and long-lasting remissions in the retrospective series | Demonstrates the potential of combining immune modulation with antiangiogenic therapy in aggressive thyroid cancer |
| Dierks et al., ATLEP (lenvatinib plus pembrolizumab) (68) | Prospective phase 2 trial | 27 patients with ATC and 8 with PDTC | Anti-PD-1 therapy combined with a VEGFR-targeting multikinase inhibitor | Primary endpoint met, with an ORR of 34.3% at 3 months | Provides prospective evidence for the combination in aggressive thyroid cancer |
| Cabanillas et al., atezolizumab plus mutation-matched targeted therapy (65) | Phase 2, nonrandomized, single center | 42 patients with unresectable or metastatic anaplastic thyroid carcinoma, assigned by genotype | Atezolizumab with vemurafenib/cobimetinib (BRAF V600E), cobimetinib (RAS or NF1/2) or bevacizumab (other) | Median OS 18.2 months overall and 43.2 months in the BRAF V600E cohort, against a historical benchmark of ~5 months | Longest overall survival published to date for systemic therapy in ATC; establishes genotype-directed therapy plus PD-L1 blockade as a leading strategy |
| Chintakuntlawar et al., pembrolizumab with chemoradiotherapy (63) | Phase 2 | 3 patients with newly diagnosed ATC | Pembrolizumab added to concurrent chemoradiotherapy as initial treatment | Initial locoregional responses occurred, but all 3 patients died within 6 months, including 2 with unexpected fatal pulmonary complications; the study was closed | Does not support routine first-line integration of the tested regimen |
| Iyer et al., salvage pembrolizumab (64) | Retrospective, single center | Patients with anaplastic thyroid carcinoma progressing on kinase inhibitors | Pembrolizumab added to ongoing kinase inhibitor therapy at progression | Median overall survival of 6.9 months from addition of pembrolizumab, with clinical benefit in a subset | Suggests a salvage role for checkpoint blockade and motivated prospective front-line combination trials |
| Hamidi et al., dabrafenib/trametinib with or without checkpoint inhibitor (66) | Retrospective cohort | Patients with BRAF V600E-mutated anaplastic thyroid carcinoma | Dabrafenib plus trametinib, with or without an added anti-PD-1 agent, with or without subsequent surgery | Improved outcomes with the addition of checkpoint inhibition; further benefit from resection of the primary tumor in selected patients | Supports combining BRAF/MEK-directed therapy with immunotherapy; requires prospective confirmation |
7.5. Combination Strategies
7.5.1. Combination with Tyrosine Kinase Inhibitors
7.5.2. Combination with BRAF- and MEK-Directed Therapy
7.5.3. Combination with Radiotherapy and Multimodal Treatment
7.5.4. Dual Checkpoint Blockade and Emerging Targets
7.6. Safety Considerations
7.7. Summary of the Current Therapeutic Position
8. Challenges, Resistance Mechanisms and Future Perspectives
8.1. Challenges in Clinical Application
| Type of Resistance | Biological Mechanism | Relevance to Thyroid Cancer | Potential Strategies to Overcome Resistance |
|---|---|---|---|
| Primary: immune-excluded tumor phenotype | Lack of effective infiltration of CD8+ cytotoxic T cells despite the presence of tumor antigens. | Some differentiated thyroid cancers exhibit limited immune cell infiltration and poor response to checkpoint blockade. | Combination with radiotherapy, antiangiogenic therapy or agents promoting immune cell recruitment. |
| Primary: low tumor immunogenicity | Low neoantigen production and limited tumor-specific immune recognition. | Most thyroid cancers have relatively low tumor mutational burden compared with highly immunogenic cancers; ATC is a partial exception. | Combination therapies that enhance antigen presentation or increase tumor immunogenicity. |
| Primary: defective antigen presentation | Loss of MHC class I expression, beta-2-microglobulin alterations or impaired interferon signaling reduce T-cell recognition. | MHC class I loss has been documented in papillary thyroid cancer and was reversible in vitro with interferon or MEK inhibition. | Restoration of antigen presentation pathways, MEK inhibition and combination immunotherapy. |
| Primary: immunosuppressive tumor microenvironment | Increased regulatory T cells, tumor-associated macrophages, MDSCs and immunosuppressive cytokines. | Particularly relevant in aggressive thyroid cancers including PDTC and ATC; lenvatinib expands PMN-MDSCs, an effect reversed by anti-PD-1 therapy. | Targeting TAMs, MDSCs, Tregs or cytokine pathways in combination with PD-1/PD-L1 inhibitors. |
| Acquired: loss of interferon signaling | Mutations or dysfunction in JAK1/JAK2 and downstream IFN-gamma signaling reduce immune-mediated tumor killing. | May explain disease progression after an initial response. | Combination approaches targeting alternative immune pathways. |
| Acquired: alternative checkpoint activation | Upregulation of inhibitory molecules such as LAG-3, TIM-3, TIGIT and VISTA after PD-1 inhibition. | Potential mechanism of resistance in patients receiving long-term checkpoint therapy. | Dual or multi-checkpoint inhibition strategies. |
| Acquired: tumor evolution and heterogeneity | Selection of resistant tumor clones with reduced antigenicity or enhanced immune escape properties. | A common challenge in advanced metastatic thyroid cancer, where clonal evolution is rapid. | Serial molecular profiling and adaptive treatment strategies. |
| Stroma-related resistance | Cancer-associated fibroblasts and extracellular matrix components restrict immune cell migration and activity. | May contribute to immune exclusion in aggressive thyroid tumors. | Stromal-targeting approaches combined with immunotherapy. |
| Angiogenesis-related resistance | Abnormal tumor vasculature limits immune cell trafficking and promotes immunosuppression. | Relevant in advanced RAI-refractory thyroid cancers and in ATC. | Combination of checkpoint inhibitors with VEGFR-targeting TKIs such as lenvatinib. |